Abstract：
UNASSIGNED: Presently, the efficacy of neonatal resuscitation techniques via interventions such as oral, nasal, and endotracheal suction for preventing meconium aspiration syndrome (MAS) after delivery has not been satisfactory.
UNASSIGNED: This study aimed to investigate the role of intratracheal instillation of budesonide on oxidative stress in MAS.
UNASSIGNED: Sixty-two neonates with MAS admitted to Huai\'an Maternity and Child Healthcare Hospital from January 2018 to June 2020 were divided into a study group (intratracheal instillation of 2 ml budesonide suspension; n = 31) and a control group (intratracheal instillation of 2 ml normal saline; n = 31). Collect data from two groups of patients and evaluate clinical outcomes, including oxygenation index (OI), as well as serum total oxidant status (TOS), total antioxidant capacity (TAC), oxidative stress index (OSI) and 8-Isoprostane before treatment and 72h after admission.
UNASSIGNED: We found no statistical differences in mortality, complication rate, total oxygen inhalation time, OI before treatment and 72h after admission between the two groups of neonates with MAS, while the duration of invasive respiratory support in the study group was significantly shorter than in the control group. Also, serum TAC, TOS, OSI and 8-isoprostane levels were not statistically different before treatment between the two groups. After 72h of admission, OSI and 8-Isoprostane in neonates with MAS in the study group were much lower than those in the control group. TOS, OSI, 8-Isoprostane in the control group and 8-Isoprostane in the study group were significantly higher than those before treatment. As for TAC and TOS, no significant differences were observed between the two groups.
UNASSIGNED: Intratracheal instillation of budesonide was shown to alleviate oxidative stress and shorten invasive ventilation time in neonates with MAS.
UNASSIGNED: This study aimed to investigate the role of intratracheal instillation of budesonide on oxidative stress in MAS.
UNASSIGNED: Sixty-two neonates with MAS admitted to Huai\'an Maternity and Child Healthcare Hospital from January 2018 to June 2020 were divided into a study group (intratracheal instillation of 2 ml budesonide suspension; n = 31) and a control group (intratracheal instillation of 2 ml normal saline; n = 31). Collect data from two groups of patients and evaluate clinical outcomes, including oxygenation index (OI), as well as serum total oxidant status (TOS), total antioxidant capacity (TAC), oxidative stress index (OSI) and 8-Isoprostane before treatment and 72h after admission.
UNASSIGNED: We found no statistical differences in mortality, complication rate, total oxygen inhalation time, OI before treatment and 72h after admission between the two groups of neonates with MAS, while the duration of invasive respiratory support in the study group was significantly shorter than in the control group. Also, serum TAC, TOS, OSI and 8-isoprostane levels were not statistically different before treatment between the two groups. After 72h of admission, OSI and 8-Isoprostane in neonates with MAS in the study group were much lower than those in the control group. TOS, OSI, 8-Isoprostane in the control group and 8-Isoprostane in the study group were significantly higher than those before treatment. As for TAC and TOS, no significant differences were observed between the two groups.
UNASSIGNED: Intratracheal instillation of budesonide was shown to alleviate oxidative stress and shorten invasive ventilation time in neonates with MAS.
摘要：
■目前，通过口服等干预措施对新生儿复苏技术的疗效，鼻部,和气管内吸引预防分娩后胎粪吸入综合征（MAS）的效果不理想。
■本研究旨在探讨气管内滴注布地奈德对MAS氧化应激的作用。
■淮安市妇幼保健院2018年1月至2020年6月收治的62例MAS新生儿，分为研究组（气管内滴注2ml布地奈德混悬液；n=31）和对照组（气管内滴注2ml生理盐水；n=31）。收集两组患者的数据并评估临床结果,包括氧合指数(OI)，以及血清总氧化剂状态（TOS），总抗氧化能力(TAC)，治疗前和入院后72h的氧化应激指数（OSI）和8-异前列腺素。
■我们发现死亡率没有统计学差异，并发症发生率,总氧气吸入时间，OI治疗前和入院72h后两组新生儿MAS,而研究组的有创呼吸支持持续时间明显短于对照组。此外，血清TAC,TOS,两组治疗前OSI和8-异前列腺素水平无统计学差异。入院72小时后，研究组新生儿MAS的OSI和8-异前列腺素明显低于对照组。TOS,OSI,对照组8-异前列腺素和研究组8-异前列腺素均明显高于治疗前。至于TAC和TOS，两组间无显著差异.
■气管内滴注布地奈德可减轻MAS新生儿的氧化应激并缩短有创通气时间。
■本研究旨在探讨气管内滴注布地奈德对MAS氧化应激的作用。
■淮安市妇幼保健院2018年1月至2020年6月收治的62例MAS新生儿，分为研究组（气管内滴注2ml布地奈德混悬液；n=31）和对照组（气管内滴注2ml生理盐水；n=31）。收集两组患者的数据并评估临床结果,包括氧合指数(OI)，以及血清总氧化剂状态（TOS），总抗氧化能力(TAC)，治疗前和入院后72h的氧化应激指数（OSI）和8-异前列腺素。
■我们发现死亡率没有统计学差异，并发症发生率,总氧气吸入时间，OI治疗前和入院72h后两组新生儿MAS,而研究组的有创呼吸支持持续时间明显短于对照组。此外，血清TAC,TOS,两组治疗前OSI和8-异前列腺素水平无统计学差异。入院72小时后，研究组新生儿MAS的OSI和8-异前列腺素明显低于对照组。TOS,OSI,对照组8-异前列腺素和研究组8-异前列腺素均明显高于治疗前。至于TAC和TOS，两组间无显著差异.
■气管内滴注布地奈德可减轻MAS新生儿的氧化应激并缩短有创通气时间。
